Dave. AMBS is not acquiring ESS to turn around and immediately sell the asset. They actually have not fully acquired it yet so talk of selling it already is a little premature. It's a fantastic product. Their biz model is to buy products like this and create value. There will not be enough value built yet to sell it. They could certainly partner but I believe they are going to get grant money to get through P2. Once P2 is done then value increased significantly, not to mention the FDA will likely fast track or breakthrough this thing to get it to patients fast.